Mind Medicine has altered its state, rebranding as Definium Therapeutics ahead of a series of phase 3 data drops on its lead psychedelic drug candidate.
The biotech, which abbreviated its old name to MindMed, is developing a formulation of the psychedelic drug LSD for use in anxiety and depression. That focus was reflected clearly in the biotech’s old name. The link between the therapeutic focus and the new name is less obvious. Stephanie Fagan, Definium’s chief corporate affairs officer, connected the dots in a statement about the rebrand.
“‘Definio’ speaks to our clear sense of direction and scientific precision, and ‘infinitum’ to being open to what hasn’t been done before and the impact we can have on the world,” Fagan said in a statement.
The combination of the two words, which are both Latin, captures how Definium is moving psychiatry forward, according to Fagan. The coming months will help show whether the company can deliver on its ambition to advance psychiatry.
Top-line data from two phase 3 trials of DT120 ODT, Definium’s orally disintegrating tablet LSD formulation, in generalized anxiety disorder are due in the second quarter and second half of 2026. Definium aims to share phase 3 data on DT120 ODT in major depressive disorder (MDD) in mid-2026. Enrollment in the MDD trial has been faster than expected, enabling Definium to pull the data forward from the second half of the year.
With a potential launch now on the horizon, the biotech raised $242.8 million in October to support the final steps in the development of DT120 ODT and the first steps in its commercialization preparations. The launch of Johnson & Johnson’s Spravato, an enantiomer of ketamine used for depression, has provided infrastructure Definium may be able to leverage when it launches DT120 ODT.
“These centers that ... have been certified under the Spravato REMS know how to navigate REMS, know how to navigate controlled substances and prior authorizations, and they have the patients. There's an obvious opportunity there,” Definium CEO Rob Barrow said at a Piper Sandler event in December.
The company has changed its Nasdaq ticker symbol from "MNMD" to "DFTX" as part of the rebrand.